Exclusive Summary

• - Patent window is clear: core patents expired (EU ~2014, US ~2019), ER launched in 2017 and generics started entering from ~2021 with less competition than IR.
• - Targets DPN and PHN populations with tens of millions of patients globally, driving steady long-term demand for pain control.
• - Once-daily ER improves adherence and convenience, aligning with NeuPSIG/ADA/AAN recommendations for neuropathic pain as first-/second-line options.
• - US-FDA GMP and US registration enable rapid multi-country submissions and distribution, reducing compliance and technical barriers.
• - Typical 50–80% price reduction versus brand, with sharper value in markets where ER is still brand-led.